To investigate predictors of response, remission, low disease activity (LDA), damage and drug discontinuation in patients with systemic lupus erythematosus (SLE) treated with belimumab.

Early disease and low baseline damage predict response to belimumab in patients with systemic lupus erythematosus

Gatto, Mariele;Saccon, Francesca;Zen, Margherita;Tincani, Angela;Bortoluzzi, Alessandra;Piga, Matteo;Vacca, Angelo;Gerli, Roberto;Larosa, Maddalena;Iaccarino, Luca;Doria, Andrea
2020

Abstract

To investigate predictors of response, remission, low disease activity (LDA), damage and drug discontinuation in patients with systemic lupus erythematosus (SLE) treated with belimumab.
2020
File in questo prodotto:
File Dimensione Formato  
Arthritis Rheumatology - 2020 - Gatto - Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in.pdf

Accesso riservato

Tipologia: Published (Publisher's Version of Record)
Licenza: Accesso privato - non pubblico
Dimensione 408.78 kB
Formato Adobe PDF
408.78 kB Adobe PDF Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11577/3336067
Citazioni
  • ???jsp.display-item.citation.pmc??? 26
  • Scopus 83
  • ???jsp.display-item.citation.isi??? 82
  • OpenAlex ND
social impact